-
公开(公告)号：US20160158268A1
公开(公告)日：2016-06-09
申请号：US15044705
申请日：2016-02-16
IPC分类号： A61K31/7076 , A61K45/06 , A61K9/00
CPC分类号： A61K31/7076 , A61K9/0048 , A61K31/495 , A61K45/06 , C07H19/16 , C07H19/167
摘要： Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
-
公开(公告)号：US20150038448A1
公开(公告)日：2015-02-05
申请号：US14517509
申请日：2014-10-17
IPC分类号： A61K31/7076 , A61K31/216 , C07H19/16
CPC分类号： A61K31/7076 , A61K9/0048 , A61K31/165 , A61K31/19 , A61K31/216 , A61K31/5575 , A61K45/06 , C07H19/16 , A61K2300/00
摘要： The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.
摘要翻译： 本发明涉及包含前列腺素类似物和腺苷受体A1激动剂的组合或试剂盒，以及使用这种组合或试剂盒降低受试者的眼内压（IOP）的方法。 本发明特别涉及以品牌Xalatan TM和化合物A销售的拉坦前列素的组合。
-
公开(公告)号：US20160367586A1
公开(公告)日：2016-12-22
申请号：US15158188
申请日：2016-05-18
IPC分类号： A61K31/7076 , A61K31/5575 , A61K9/00
CPC分类号： A61K31/7076 , A61K9/0048 , A61K31/165 , A61K31/19 , A61K31/216 , A61K31/5575 , A61K45/06 , C07H19/16 , A61K2300/00
摘要： The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.
-
公开(公告)号：US20150080330A1
公开(公告)日：2015-03-19
申请号：US14552160
申请日：2014-11-24
IPC分类号： A61K9/00 , A61K45/06 , A61K31/7076 , C07H19/16
CPC分类号： A61K31/7076 , A61K9/0048 , A61K31/495 , A61K45/06 , C07H19/16 , C07H19/167
摘要： Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
摘要翻译： 本文提供了使用N6-环戊基腺苷（CPA），CPA衍生物或前药或CPA增强的角膜通透性制剂降低人眼内压（IOP）的方法。 在一个实施方案中，本发明涉及可透过角膜的CPA衍生物或前药。 在另一个实施方案中，本发明涉及某些化合物在人受试者中用于减少和/或控制治疗青光眼或高眼压症（OHT）的升高或异常波动的IOP的用途。
-
公开(公告)号：US20140018314A1
公开(公告)日：2014-01-16
申请号：US13909288
申请日：2013-06-04
IPC分类号： C07H19/167
CPC分类号： A61K31/7076 , A61K9/0048 , A61K31/495 , A61K45/06 , C07H19/16 , C07H19/167
摘要： Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
摘要翻译： 本文提供了使用N6-环戊基腺苷（CPA），CPA衍生物或前药或CPA增强的角膜通透性制剂降低人眼内压（IOP）的方法。 在一个实施方案中，本发明涉及可透过角膜的CPA衍生物或前药。 在另一个实施方案中，本发明涉及某些化合物在人受试者中用于减少和/或控制治疗青光眼或高眼压症（OHT）的升高或异常波动的IOP的用途。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
